Federal Regulatory Agency
Appears in 37 stories
Reviewing antibiotic candidates under expedited pathways
No genuinely new class of antibiotic has reached patients since 1987. In the nearly four decades since, bacteria have steadily evolved resistance to existing drugs, and carbapenem-resistant Acinetobacter baumannii—a hospital-acquired pathogen that kills up to 60 percent of ventilated pneumonia patients—now sits atop the World Health Organization's list of critical-priority threats. On March 16, 2026, Swiss biotech BioVersys received clearance from the United States Food and Drug Administration (FDA) to begin enrolling American patients in a Phase 3 pivotal trial of BV100, a drug that cut 28-day mortality in half during earlier testing.
Updated Yesterday
Approved PureSee without contrast sensitivity warning based on clinical data
For a decade, patients choosing premium lenses during cataract surgery have faced a trade-off: better range of vision, but dimmer, lower-contrast sight—especially in low light. On March 12, 2026, the Food and Drug Administration approved Johnson & Johnson's TECNIS PureSee, the first extended depth of focus lens cleared in the United States without a warning for loss of contrast sensitivity. In clinical trials, 97% of patients reported no bothersome visual disturbances like halos or glare.
Updated 5 days ago
Approved leucovorin for rare condition; declined autism indication
In September 2025, White House officials told parents of autistic children that a cheap, generic drug called leucovorin might improve their children's speech and behavior. Prescriptions surged 71% in the following months, pharmacies ran dry, and the Food and Drug Administration (FDA) allowed emergency imports from Canada and Spain. On March 10, 2026, the FDA approved leucovorin — but only for a genetic condition so rare that fewer than 50 cases have ever been identified worldwide, not for autism.
Updated 7 days ago
Granted accelerated approval for Ojemda; confirmatory Phase 3 trial ongoing
For decades, children with relapsed brain tumors had no approved targeted treatment. That changed in April 2024 when the Food and Drug Administration (FDA) cleared Ojemda, a once-weekly pill for pediatric low-grade glioma, the most common childhood brain cancer. Now the company behind it, Day One Biopharmaceuticals, has agreed to be acquired by France's Servier for $2.5 billion in cash, a 68% premium over its previous closing share price.
Updated Mar 6
Reached PDUFA decision deadline on Sotyktu for psoriatic arthritis
For most of the past decade, people with psoriatic arthritis who wanted a pill instead of an injection had one real option: Janus kinase (JAK) inhibitors, a class of oral drugs that the Food and Drug Administration (FDA) slapped with its strongest safety warning in 2021 after a major trial linked them to higher rates of heart attacks, blood clots, cancer, and death. On March 6, the FDA reached its decision deadline on whether to approve the first oral drug from a different class entirely—Bristol Myers Squibb's Sotyktu (deucravacitinib), a selective tyrosine kinase 2 (TYK2) inhibitor—for adults with active psoriatic arthritis, a condition that causes painful joint inflammation in roughly 1.5 million Americans.
Granted Breakthrough Therapy Designation to zorevunersen
For nearly five decades, children born with Dravet syndrome—a severe genetic epilepsy that causes hundreds of seizures per month, cognitive decline, and a mortality rate between 15 and 20 percent—had no treatment that addressed the underlying cause. Every available drug, including two approved in the past eight years, could only partially suppress symptoms. On March 5, 2026, the New England Journal of Medicine published the first clinical evidence that a drug can modify the disease itself: zorevunersen, an antisense oligonucleotide that boosts protein production from the healthy copy of the gene responsible for the condition, reduced motor seizures by up to 91 percent in 81 children and sustained improvements in cognition and behavior over three years.
Updated Mar 5
Developing framework for generative AI medical devices
The United States Food and Drug Administration (FDA) has cleared more than 1,250 artificial intelligence-enabled medical devices since it began tracking them — nearly all of them narrow systems that read scans or flag anomalies without ever speaking to a patient. On March 3, 2026, a startup called RecovryAI announced that the FDA granted Breakthrough Device Designation to its Virtual Care Assistants, making it the first patient-facing product built on a generative large language model (LLM) to enter the agency's accelerated review pipeline. The device is designed to be prescribed after joint replacement surgery, checking in with patients twice daily about sleep, activity, and diet, and escalating concerns to the surgical team.
Updated Mar 3
Approved three achondroplasia treatments: Voxzogo (daily), YUVIWEL (weekly), reviewing BridgeBio filing
For the estimated 250,000 people worldwide living with achondroplasia—the most common genetic cause of dwarfism—the only approved treatment required daily injections until BioMarin's Voxzogo. On February 12, 2026, BridgeBio reported that its oral pill achieved a 2.10 cm/year increase in height growth over placebo in a Phase 3 trial, exceeding Voxzogo's 1.57 cm/year gain and marking the first statistically significant improvement in body proportionality; two weeks later on February 27, the FDA approved Ascendis Pharma's once-weekly YUVIWEL (navepegritide) for children aged 2 and older.
Updated Mar 1
Has approved Dupixent nine times across distinct indications
When the Food and Drug Administration (FDA) approved Dupixent for severe eczema in 2017, it was one drug for one disease. Nine years later, the same molecule has been approved for nine separate conditions, from asthma to a chronic fungal sinus infection that previously had no approved treatment at all. The latest approval, granted on February 24, 2026, covers allergic fungal rhinosinusitis (AFRS), a condition that traps patients in a cycle of repeated sinus surgeries. In a pivotal trial, Dupixent reduced the need for additional surgeries and steroid courses by 92%.
Updated Feb 24
Issued draft guidance creating the plausible mechanism framework
For decades, the Food and Drug Administration (FDA) required the same basic proof for every drug: show it works in a controlled trial with enough patients to be statistically meaningful. That standard made sense for common diseases but created an impossible barrier for conditions affecting a handful of people worldwide. On February 23, 2026, the FDA issued draft guidance creating a fundamentally different standard—called the "plausible mechanism" framework—that would let developers of individualized gene-editing and ribonucleic acid (RNA) therapies win full approval by demonstrating their treatment targets the root genetic cause, successfully edits or engages the target, and improves outcomes compared to the disease's documented natural course.
Updated Feb 23
Continuing active review of psychiatric drug applications
Every atypical antipsychotic approved since the early 1990s has worked the same basic way: blocking dopamine receptors in the brain. In the past 17 months, the Food and Drug Administration (FDA) has approved three new psychiatric drugs—including Cobenfy, the first schizophrenia treatment with a genuinely novel mechanism in over 50 years, and now Bysanti, a new chemical entity from Vanda Pharmaceuticals cleared for both bipolar I disorder and schizophrenia. For the roughly 7 million Americans living with these conditions, the options just got meaningfully wider.
Updated Feb 21
Approved the venetoclax-acalabrutinib combination
For decades, patients diagnosed with chronic lymphocytic leukemia—the most common adult leukemia in Western countries, affecting roughly 23,000 Americans each year—faced a difficult choice: endure rounds of intravenous chemotherapy with harsh side effects, or take targeted pills indefinitely, sometimes for life. On February 20, 2026, the Food and Drug Administration (FDA) approved a combination of two oral drugs, venetoclax and acalabrutinib, that eliminates both burdens. Patients take pills for roughly one year, then stop. In a trial of 867 patients, 77% remained cancer-free at three years.
Updated Feb 20
Implementing three-pronged domestic manufacturing incentive strategy
Only 9% of the factories that make active pharmaceutical ingredients for American medicines are located in the United States. China and India account for roughly two-thirds of the rest. For decades, this arrangement kept drug prices low and went largely unchallenged — until the COVID-19 pandemic exposed how quickly a foreign export ban could empty American pharmacy shelves. Now the Food and Drug Administration (FDA) is quietly assembling what amounts to a three-layer incentive stack designed to reverse that dependency: the PreCheck pilot program to accelerate new factory buildouts, a priority review track for generics manufactured entirely on U.S. soil, and a proposed three-year fee waiver for new domestic plants under the next Generic Drug User Fee Amendments (GDUFA) reauthorization.
Undergoing significant regulatory changes under new leadership
For 63 years, the Food and Drug Administration required drugmakers to prove their products worked in at least two rigorous clinical trials before Americans could take them. On February 18, 2026, Commissioner Marty Makary formally ended that standard, announcing that one trial will now be the "default position" for all new drugs—not just treatments for rare and fatal diseases, but medications for common conditions affecting millions of patients. In accompanying articles published in the New England Journal of Medicine and JAMA, Makary and Deputy Commissioner Vinay Prasad emphasized that the single-trial standard does not eliminate evidence requirements; instead, sponsors must provide "confirmative evidence" through mechanistic data, findings from related indications, animal models, real-world evidence, or data from drugs in the same class.
Regulator of medical devices including bone grafts
For 24 years, Medtronic's INFUSE bone graft has followed a winding path through FDA approval, off-label controversy, lawsuits, and now expansion. The Food and Drug Administration (FDA) just granted INFUSE approval for transforaminal lumbar interbody fusion (TLIF) procedures—making it the only growth factor bone graft approved for two-level spinal constructs and the only one cleared for anterior, oblique, and transforaminal approaches.
Updated Feb 17
Supporting transition from animal testing to alternative models
For the first time, scientists have grown a miniature human spinal cord in a laboratory, injured it, and watched it heal. Northwestern University researchers published findings in Nature Biomedical Engineering showing their stem-cell-derived organoid accurately replicates cell death, inflammation, and scar formation seen in real spinal cord injuries—then demonstrated significant tissue repair when treated with an experimental therapy.
Updated Feb 16
Faces pressure to revise statin labels
More than 200 million people worldwide take statins for heart health. For decades, package inserts have warned them about 66 potential side effects, from memory loss to depression to muscle pain. A new analysis of 23 major clinical trials—the largest ever conducted—found that 62 of those warnings are unsupported by evidence.
Updated Feb 15
Granted approval; previously designated Optune Pax as Breakthrough Device in December 2024
Pancreatic cancer has been oncology's grimmest frontier. The five-year survival rate sits at 13 percent—and for decades, patients diagnosed with locally advanced disease had essentially one option: chemotherapy that extended life by months, not years. On February 11, 2026, that changed. The Food and Drug Administration approved Optune Pax, a portable device that delivers alternating electrical fields to the abdomen, marking the first new FDA-approved treatment for locally advanced pancreatic cancer in nearly three decades.
Updated Feb 13
Primary regulator of AI medical devices in the United States
Radiologists have spent decades reading brain scans the same way: study the images, cross-reference patient history, dictate findings, move to the next case. A single magnetic resonance imaging (MRI) interpretation can take 20 minutes. Now an artificial intelligence system developed at the University of Michigan can do it in seconds—and flag which patients need emergency intervention before a human ever sees the scan.
Adapting approval pathways for AI-driven precision medicine
For decades, cancer drug trials have failed at a rate exceeding 95%—burning through $50-60 billion annually on treatments tested in patients who were never likely to respond. On April 17, 2025, researchers from AstraZeneca and Tempus AI published results in Cancer Cell showing that the Predictive Biomarker Modeling Framework (PBMF)—a machine learning system using contrastive learning—can identify, from existing clinical data, which cancer patients will survive longer on immunotherapy versus chemotherapy. Applied retrospectively to completed phase 3 trials, the system improved survival outcomes by 15% compared to traditional patient selection.
Updated Feb 11
Reviewing BioCardia Pre-Submission
For two decades, scientists have known how to grow cells and engineer genes that could repair damaged hearts. The problem has been getting those therapies to the right spot. On February 10, 2026, BioCardia filed for FDA approval of the Helix catheter—a device that threads through blood vessels to inject treatments directly into heart muscle. If approved, it would be the first system of its kind cleared for use in the United States.
Updated Feb 10
Evaluating rilzabrutinib under breakthrough therapy pathway
For 50,000 Americans living with warm autoimmune hemolytic anemia, there has never been a treatment specifically designed for their disease. On February 9, 2026, the Food and Drug Administration (FDA) granted breakthrough therapy designation to rilzabrutinib—marking the first time a Bruton's tyrosine kinase (BTK) inhibitor has reached this milestone for the condition. The designation signals the FDA's recognition that this drug may offer substantial improvement over existing therapies.
Updated Feb 9
Approved suzetrigine for moderate-to-severe acute pain
For more than 20 years, doctors facing patients in severe pain had two choices: prescribe opioids that risked addiction, or use weaker alternatives that often fell short. On January 30, 2025, the Food and Drug Administration (FDA) approved suzetrigine—brand name Journavx—ending that drought as the first entirely new class of pain medication since the late 1990s.
Updated Feb 7
Reviewing Anaphylm NDA with January 31, 2026 target date
For nearly four decades, Americans facing life-threatening allergic reactions had exactly one option: stab themselves with a needle. The EpiPen and its competitors delivered epinephrine effectively, but needle phobia kept roughly 30% of patients from using their prescribed devices during emergencies—contributing to preventable deaths. Now the needle era is ending. The Food and Drug Administration (FDA) approved the first needle-free alternative, a nasal spray called neffy, in August 2024. On February 2, 2026, the FDA issued a Complete Response Letter for Anaphylm, a dissolvable film placed under the tongue, rejecting the application but limiting deficiencies to human factors and packaging rather than safety or efficacy concerns. Aquestive Therapeutics expects to resubmit in the third quarter of 2026 after conducting a redesigned human factors validation study and a supporting pharmacokinetics study.
Updated Feb 5
Regulatory decision triggered underlying dispute
Delaware's courts have long served as the final word on American corporate disputes. On January 12, 2026, the state's Supreme Court issued a ruling that will reshape how companies structure billion-dollar acquisitions: when a merger agreement specifies a particular path to an earnout payment, courts will not rescue sellers who failed to negotiate alternatives.
Updated Feb 4
Granted breakthrough device designations and approved first non-invasive spinal cord stimulator
For decades, blood pressure instability has silently debilitated people with spinal cord injuries—78% of those with cervical injuries experience dangerous drops when sitting upright, yet only 28% receive treatment that actually works. ONWARD Medical just enrolled the first participant in a pivotal trial testing whether an implanted spinal cord stimulator can solve this problem by restoring the autonomic signals that paralysis disrupts.
Approving new breast cancer treatments at accelerated pace
The U.S. breast cancer death rate has fallen 44% since its 1989 peak—an estimated 546,000 lives saved. Susan G. Komen's 2026 Progress Outlook attributes three-quarters of this decline to treatment advances and the remainder to earlier detection through mammography screening.
Updated Feb 3
Overseeing Neuralink's U.S. trials
Two years ago, Neuralink implanted a coin-sized chip in Noland Arbaugh's brain—the first human to receive the company's Telepathy device. As of January 28, 2026, twenty-one people across four countries are using Neuralink implants to control computers, phones, and robotic arms with their thoughts. Several participants now exceed the cursor-control speed of able-bodied people using a mouse.
Updated Feb 2
Approved Yartemlea after extended review process
For decades, patients who developed transplant-associated thrombotic microangiopathy (TA-TMA) after stem cell transplants faced a grim reality: a life-threatening complication with no approved treatment. Mortality rates for high-risk cases reached 80-90%. In December 2025, the FDA approved Yartemlea, the first therapy for this condition, marking Seattle-based Omeros Corporation's first drug approval after 31 years. The company launched commercially on January 2, 2026, announced pricing at $36,000 per vial on January 7, and by late January both adult and pediatric patients were receiving treatment at transplant centers nationwide.
Updated Jan 31
Developing cancer vaccine regulatory framework
Metastatic breast cancer typically kills most patients within five years. A small group of women vaccinated in a Duke University clinical trial two decades ago have defied that prognosis entirely—all remain alive today. Researchers discovered these survivors still carry specialized immune cells capable of recognizing their cancer, pointing to a mechanism that could make therapeutic cancer vaccines work reliably.
Actively phasing out animal testing requirements in favor of organoid and AI-based methods
Johns Hopkins engineers grew miniature brains from patients' skin cells and discovered each psychiatric disorder has its own electrical fingerprint. The organoids diagnosed schizophrenia and bipolar disorder with 83% accuracy just by monitoring neural firing patterns—rising to 92% after gentle electrical stimulation. Machine learning algorithms spotted the differences invisible to human observers. The technology gained mainstream attention in January 2026 when NPR highlighted both the promise and ethical complexities of brain organoid research. By late January 2026, the American Psychiatric Association outlined plans to integrate biological biomarkers—including blood tests, neuroimaging, and digital monitoring—into the next DSM revision, signaling psychiatry's institutional shift toward biology-based diagnosis.
Approved YUVEZZI as fourth presbyopia eye drop
For 240 years, the solution to presbyopia—the gradual loss of near-vision that affects nearly everyone over 45—has been essentially the same: put lenses in front of your eyes. Benjamin Franklin invented bifocals in 1785. Today, two billion people worldwide rely on reading glasses. On January 29, 2026, the Food and Drug Administration approved YUVEZZI (carbachol and brimonidine tartrate ophthalmic solution), the first dual-agent eye drop for treating this universal condition, marking a pivotal moment in pharmacological presbyopia treatment.
Updated Jan 30
Reviewing sparsentan sNDA with new April 13, 2026 PDUFA date
No FDA-approved treatment for focal segmental glomerulosclerosis (FSGS) has ever existed. For the 40,000 Americans with this rare kidney disease—which drives half of patients to kidney failure within a decade—the only options have been off-label immunosuppressants with mixed results. On January 13, 2026, that was supposed to change. Instead, the FDA extended its review of sparsentan by three months, requesting more data on clinical benefit. The announcement triggered a 33% intraday stock plunge and sparked multiple shareholder investigations into potential securities law violations. Two weeks later, CEO Eric Dube sold $1.56 million in company stock, a transaction drawing scrutiny given its timing.
Granted Breakthrough Therapy Designation
Cancer vaccines have promised to train the immune system against tumors for decades. None has delivered a durable, replicable benefit—until now. On January 20, 2026, Moderna and Merck reported that their personalized mRNA vaccine, combined with the immunotherapy Keytruda, cut the risk of melanoma recurrence or death by 49% at five years in a Phase 2b trial of 157 patients. The sustained result—identical to the three-year mark—suggests the vaccine permanently reprograms immune surveillance rather than offering temporary protection.
Updated Jan 25
Approved generic CF drugs after patent expiration
A generic version of Trikafta—the breakthrough cystic fibrosis drug that extends lives by decades—hit the market at $12,750 per year. That's 95% cheaper than Vertex Pharmaceuticals' brand-name version, which costs over $300,000 annually and has generated billions while remaining out of reach for patients in developing nations and many Americans with inadequate insurance.
Updated Jan 12
Approved six CAR-T therapies; removed REMS requirements in 2025
Gene therapy killed Jesse Gelsinger in 1999. His death triggered FDA shutdowns, lawsuits, and nearly ended the field. Fast forward to December 2025: British scientists published results showing that base-edited immune cells—a 'living drug'—achieved deep remissions in 82% of children with previously incurable T-cell leukemia. Three years after treatment, 64% remain disease-free. Some patients are off treatment entirely.
Updated Jan 9
Developing joint CDER-CBER guidance on plausible mechanism pathway
In August 2024, KJ Muldoon was born with a death sentence encoded in his DNA—a single broken letter among three billion that left his body unable to process protein. Six months later, he walked out of Children's Hospital of Philadelphia, cured by a gene-editing therapy that didn't exist when he was diagnosed. The treatment was designed, manufactured, approved, and delivered in 180 days.
Updated Jan 7
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
